Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM-101 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Immodulon Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Intradermal
01
Overview
IMM-101 + gemcitabine + nab-paclitaxel is a **combination regimen** used or investigated in the treatment of advanced pancreatic cancer. IMM-101 is an immunotherapeutic comprising heat-killed whole cell *Mycobacterium obuense*, which acts by stimulating the innate and adaptive immune systems, particularly enhancing dendritic cell maturation and promoting cytotoxic T cell responses[3][7]. Gemcitabine is a nucleoside analogue chemotherapy (cytotoxic antimetabolite) inhibiting DNA synthesis in dividing cells[8], and nab-paclitaxel is paclitaxel bound to albumin nanoparticles, facilitating drug delivery to tumor cells and disrupting microtubule dynamics during cell division[4][8]. Clinical studies have assessed IMM-101 with gemcitabine for metastatic pancreatic cancer, showing improved (though modest) overall survival compared to gemcitabine alone[7]. Nab-paclitaxel with gemcitabine is considered a standard first-line regimen for metastatic pancreatic cancer, and the triple combination is under investigation, primarily for enhancing antitumor immune response and cytotoxicity[2][3][6][7].
- Other names
- IMM-101 + gemcitabine + nab-paclitaxel
02
Targets
CDA (Cytidine deaminase)Microtubule
Beyond the preview
Go deeper on IMM-101 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM-101 + gemcitabine + nab-paclitaxel.